Cargando…
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial
INTRODUCTION: The aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to receive anastrozole (A). METHODS: Pre-treatment BMD of 213 pati...
Autores principales: | Markopoulos, Christos, Tzoracoleftherakis, Evagelos, Polychronis, Athanassios, Venizelos, Basileios, Dafni, Urania, Xepapadakis, Grigorios, Papadiamantis, John, Zobolas, Vasilios, Misitzis, John, Kalogerakos, Kyriakos, Sarantopoulou, Angeliki, Siasos, Nikolaos, Koukouras, Dimitrios, Antonopoulou, Zoh, Lazarou, Spyros, Gogas, Helen |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2879572/ https://www.ncbi.nlm.nih.gov/pubmed/20398352 http://dx.doi.org/10.1186/bcr2565 |
Ejemplares similares
-
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial
por: Markopoulos, Christos, et al.
Publicado: (2012) -
Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy
por: Markopoulos, Christos, et al.
Publicado: (2009) -
Improvement of Bone Physiology and Life Quality Due to Association of Risedronate and Anastrozole
por: Monda, Vincenzo, et al.
Publicado: (2017) -
Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia
por: Sestak, Ivana, et al.
Publicado: (2019) -
Plasma cell gingivitis - A rare case related to Colocasia (arbi) leaves
por: Bali, Deepika, et al.
Publicado: (2012)